Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Inozyme Pharma, Inc. - Common Stock
(NQ:
INZY
)
4.000
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inozyme Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
June 20, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders
May 27, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
May 21, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 19, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders
May 18, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
Gold Down Over 1%; Flowers Foods Posts Weak Earnings
↗
May 16, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
May 16, 2025
Via
Benzinga
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens
↗
May 16, 2025
The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.
Via
Stocktwits
Synergy CHC Corp. (NASDAQ: SNYR) Reports Strong Q1, Signals 2025 Expansion in GLP-1 and Global Markets – More Stocks Inside
May 16, 2025
Via
AB Newswire
US Stocks Edge Higher; Consumer Sentiment Falls In May
↗
May 16, 2025
Via
Benzinga
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders
May 16, 2025
From
Halper Sadeh LLC
Via
Business Wire
BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover
↗
May 16, 2025
Inozyme Pharma is working on an enzyme replacement therapy for ENPP1 deficiency in children.
Via
Investor's Business Daily
Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders
May 16, 2025
From
Ademi & Fruchter LLP
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 16, 2025
Via
Benzinga
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 14, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
April 10, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
March 10, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
February 21, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
January 10, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at Upcoming Investor Conferences
November 11, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 05, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
October 24, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
October 17, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
October 07, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
September 26, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
↗
September 12, 2024
Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to treat rare diseases like ENPP1 and ABCC6 deficiencies.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
